J Gastric Cancer.  2018 Mar;18(1):82-89. 10.5230/jgc.2018.18.e7.

Early Detection is Important to Reduce the Economic Burden of Gastric Cancer

• Kim JH
• Kim SS
• Lee JH
• Jung DH
• Cheung DY
• Chung WC
• Park SH

• KMID: 2414549
• DOI: http://doi.org/10.5230/jgc.2018.18.e7

Abstract

PURPOSE
Early detection of gastric cancer is important to improve prognosis. Early detection enables local treatment, such as endoscopic submucosal dissection (ESD). Therefore, we investigated whether early detection of gastric cancer could reduce healthcare costs by comparison according to stage and treatment modalities.
MATERIALS AND METHODS
Medical care costs were investigated according to tumor stage and initial treatment modality in 1,188 patients newly diagnosed with gastric cancer at 7 medical institutions from December 2011 to June 2012. Total medical care costs during the first-year after diagnosis (total first-year costs) were examined, including the costs of initial treatment, post-initial treatment, and inpatient and outpatient visits.
RESULTS
Stage I (75.3%) was the most common cancer stage. ESD was the second most common treatment following surgery. Total first-year costs increased significantly from stages I to IV. The costs of initial treatment and post-initial treatment were lowest in patients with stage I cancer. Among patients with stage I cancer, total first-year costs were significantly lower when treated by ESD; in particular, initial ESD treatment costs were much lower than others.
CONCLUSIONS
The cost of healthcare has increased significantly with increasing cancer stages. ESD can greatly reduce medical care costs of gastric cancer. Thus, early detection of gastric cancer is important to reduce healthcare costs.

Keyword

Stomach neoplasms; Endoscopic submucosal dissection; Healthcare costs; Cancer staging; Early detection of cancer

MeSH Terms

Delivery of Health Care
Diagnosis
Early Detection of Cancer
Health Care Costs
Humans
Inpatients
Neoplasm Staging
Outpatients
Prognosis
Stomach Neoplasms*

Figure

• 

  Fig. 1 Medical care costs according to cancer stage. Total first-year costs increased significantly from stage I through stage IV. Initial treatment and post-initial treatment costs were the lowest for stage I (“<” indicates a significant difference).

• 

  Fig. 2 Medical care costs according to initial treatment modality in stage I cases. Initial stage I treatment modalities included ESD, OP, and OP with adjuvant CTx. Total first-year costs for stage I cancer were significantly lower for ESD, and, particularly, initial ESD treatment costs were lower than those of the other treatment modalities (“<” indicates a significant difference).ESD = endoscopic submucosal dissection; OP = surgery; CTx = chemotherapy.

Reference

1. Goto O, Fujishiro M, Kodashima S, Ono S, Omata M. Outcomes of endoscopic submucosal dissection for early gastric cancer with special reference to validation for curability criteria. Endoscopy. 2009; 41:118–122. PMID: 19214889.

2. Peppercorn J. The financial burden of cancer care: do patients in the US know what to expect? Expert Rev Pharmacoecon Outcomes Res. 2014; 14:835–842. PMID: 25269513.

3. Guy GP Jr, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013; 31:3749–3757. PMID: 24043731.

4. Haga K, Matsumoto K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of the stomach cancer in Japan - a time trend and future projections. BMC Health Serv Res. 2013; 13:283. PMID: 23879739.

5. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991; 29:40–49. PMID: 1986176.

6. Li TY, Hsieh JS, Lee KT, Hou MF, Wu CL, Kao HY, et al. Cost trend analysis of initial cancer treatment in Taiwan. PLoS One. 2014; 9:e108432. PMID: 25279947.

7. Stump TK, Eghan N, Egleston BL, Hamilton O, Pirollo M, Schwartz JS, et al. Cost concerns of patients with cancer. J Oncol Pract. 2013; 9:251–257. PMID: 23943901.

8. Dinan MA, Robinson TJ, Zagar TM, Scales CD Jr, Curtis LH, Reed SD, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999–2007. Int J Radiat Oncol Biol Phys. 2012; 82:e781–e786. PMID: 22331001.

9. Kim SG, Hahm MI, Choi KS, Seung NY, Shin HR, Park EC. The economic burden of cancer in Korea in 2002. Eur J Cancer Care (Engl). 2008; 17:136–144. PMID: 18302650.

10. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat. 2014; 46:124–130. PMID: 24851103.

11. Kim SY, Kim SG, Park JH, Park EC. Costs of initial cancer care and its affecting factors. J Prev Med Public Health. 2009; 42:243–250. PMID: 19675401.

12. Veenstra CM, Regenbogen SE, Hawley ST, Griggs JJ, Banerjee M, Kato I, et al. A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care. 2014; 52:957–962. PMID: 25304021.

13. Macalindong SS, Kim KH, Nam BH, Ryu KW, Kubo N, Kim JY, et al. Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. BMC Cancer. 2018; 18:73. PMID: 29329569.

14. Kim SG, Seo HS, Lee HH, Song KY, Park CH. Comparison of the differences in survival rates between the 7th and 8th editions of the AJCC TNM staging system for gastric adenocarcinoma: a single-institution study of 5,507 patients in Korea. J Gastric Cancer. 2017; 17:212–219. PMID: 28970951.

15. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100:888–897. PMID: 18544740.

16. Ekwueme DU, Yabroff KR, Guy GP Jr, Banegas MP, de Moor JS, Li C, et al. Medical costs and productivity losses of cancer survivors--United States, 2008–2011. MMWR Morb Mortal Wkly Rep. 2014; 63:505–510. PMID: 24918485.

17. Guy GP Jr, Yabroff KR, Ekwueme DU, Smith AW, Dowling EC, Rechis R, et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff (Millwood). 2014; 33:1024–1031. PMID: 24889952.

18. Dowling EC, Chawla N, Forsythe LP, de Moor J, McNeel T, Rozjabek HM, et al. Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. Cancer. 2013; 119:3393–3401. PMID: 23794146.